Syros Pharmaceuticals Inc (NASDAQ:SYRS) Director Srinivas Akkaraju purchased 109,774 shares of the stock in a transaction on Thursday, December 14th. The shares were purchased at an average price of $9.03 per share, with a total value of $991,259.22. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Shares of Syros Pharmaceuticals Inc (SYRS) opened at $8.98 on Friday. Syros Pharmaceuticals Inc has a one year low of $6.30 and a one year high of $24.38.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.53) earnings per share for the quarter, meeting the consensus estimate of ($0.53). analysts expect that Syros Pharmaceuticals Inc will post -2.1 earnings per share for the current fiscal year.

SYRS has been the subject of several analyst reports. Zacks Investment Research lowered shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Cowen restated a “buy” rating on shares of Syros Pharmaceuticals in a report on Monday. Oppenheimer restated a “buy” rating and set a $28.00 price target on shares of Syros Pharmaceuticals in a report on Thursday, December 7th. ValuEngine lowered shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 22nd. Finally, Cann restated a “buy” rating and set a $28.00 price target on shares of Syros Pharmaceuticals in a report on Monday, August 21st. One analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $26.14.

Large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its stake in shares of Syros Pharmaceuticals by 157.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 30,024 shares of the company’s stock valued at $483,000 after acquiring an additional 18,382 shares in the last quarter. Ark Investment Management LLC increased its stake in shares of Syros Pharmaceuticals by 114.7% in the 2nd quarter. Ark Investment Management LLC now owns 17,705 shares of the company’s stock valued at $285,000 after acquiring an additional 9,460 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Syros Pharmaceuticals by 189.6% in the 2nd quarter. Vanguard Group Inc. now owns 382,603 shares of the company’s stock valued at $6,156,000 after acquiring an additional 250,507 shares in the last quarter. FMR LLC increased its stake in shares of Syros Pharmaceuticals by 11.9% in the 2nd quarter. FMR LLC now owns 3,926,998 shares of the company’s stock valued at $63,185,000 after acquiring an additional 418,061 shares in the last quarter. Finally, Teachers Advisors LLC increased its stake in shares of Syros Pharmaceuticals by 360.5% in the 2nd quarter. Teachers Advisors LLC now owns 22,718 shares of the company’s stock valued at $366,000 after acquiring an additional 17,785 shares in the last quarter. Institutional investors own 58.02% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Syros Pharmaceuticals Inc (SYRS) Director Srinivas Akkaraju Acquires 109,774 Shares” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/12/15/syros-pharmaceuticals-inc-syrs-director-srinivas-akkaraju-acquires-109774-shares.html.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.